肝硬化对达利雷生药代动力学、代谢及耐受性的影响
本研究为单剂量、开放标签I期研究,纳入轻度(Child-Pugh A,N=8)或中度(Child-Pugh B,N=8)肝硬化患者及匹配健康对照(N=8),口服达利雷生25 mg。结果显示中度肝硬化损害未结合达利雷生的肝清除并延长半衰期,建议Child-Pugh B患者不超过25 mg,Child-Pugh A无需调整剂量,Child-Pugh C应避免使用。
要点
- Child-Pugh B患者未结合达利雷生AUC0-inf几何均值比1.60,半衰期加倍,剂量不应超过25 mg。
- Child-Pugh A患者无需调整剂量,Child-Pugh C肝硬化患者建议避免使用达利雷生。
- 25 mg达利雷生在研究人群中未发现安全性问题,不良事件均为短暂轻中度。
核心结论
- 中度肝硬化导致未结合达利雷生肝清除受损并延长半衰期,Child-Pugh B患者25 mg剂量不应超过。
- Child-Pugh A患者无需剂量调整,Child-Pugh C肝硬化患者建议避免使用达利雷生。
研究设计与样本
- 单剂量、开放标签I期研究,纳入轻度(Child-Pugh A,N=8)或中度(Child-Pugh B,N=8)肝硬化患者及匹配健康对照(N=8)。
- 受试者口服达利雷生25 mg,给药后72小时内采血进行药代动力学评估。
主要发现
- 与健康受试者相比,Child-Pugh A患者总达利雷生AUC0-inf和Cmax的几何均值比(GMR,90%CI)分别为0.51(0.28-0.92)和0.50(0.35-0.72)。
- Child-Pugh B患者总达利雷生AUC0-inf和Cmax的GMR(90%CI)分别为0.74(0.39-1.41)和0.42(0.29-0.60),半衰期GMR为2.09(1.32-3.30)。
- Child-Pugh B患者未结合达利雷生AUC0-inf的GMR(90%CI)为1.60(0.93-2.73),表观血浆清除率GMR为0.63(0.37-1.07),半衰期同样加倍。
- Child-Pugh A患者未结合达利雷生PK与健康受试者无差异,且肝硬化患者两种主要代谢物的代谢比值高于健康受试者。
- 所有治疗中出现的不良事件均为短暂、轻或中度,未发现其他治疗相关效应。
关键数值与推荐
- Child-Pugh B患者达利雷生25 mg剂量不应超过。
- Child-Pugh A患者无需剂量调整。
- Child-Pugh C肝硬化患者建议避免使用达利雷生。
临床怎么用
- 对Child-Pugh B肝硬化失眠患者,使用达利雷生时剂量不应超过25 mg。
- Child-Pugh A肝硬化患者可使用达利雷生25 mg而无需调整剂量。
- Child-Pugh C肝硬化患者应避免使用达利雷生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Daridorexant is a dual orexin receptor antagonist in clinical development for insomnia. As daridorexant is cleared mainly via cytochrome P450 (CYP) 3A4, the effect of hepatic impairment on the pharmacokinetics (PK), metabolism, and tolerability of daridorexant was evaluated. Sleep disorders are common in patients with liver cirrhosis and, therefore, sleep-promoting drugs with a better tolerability than currently available would be preferable, a premise that dual orexin receptor antagonists may fulfill. METHODS: This was a single-dose, open-label, phase I study. Subjects with mild (Child-Pugh A, N = 8) or moderate (Child-Pugh B, N = 8) liver cirrhosis and matched healthy control subjects (N = 8) received 25 mg of daridorexant orally. Blood samples were collected for 72 h post-dose for PK assessments of daridorexant and three major metabolites. RESULTS: Compared with healthy subjects, patients showed a decrease in total daridorexant area under the plasma concentration-time curve from zero to infinity (AUC0-inf) and maximum plasma concentration with a geometric mean ratio (GMR, 90% confidence interval [CI]) of 0.51 (0.28-0.92) and 0.50 (0.35-0.72) in Child-Pugh A and 0.74 (0.39-1.41) and 0.42 (0.29-0.60) in Child-Pugh B patients, respectively. Furthermore, the median time to reach maximum plasma concentration was slightly delayed (1.0 h [90% CI 0.0-2.0] in Child-Pugh A patients and 0.5 h [90% CI 0.0-1.5] in Child-Pugh B patients), while for Child-Pugh B patients, a doubling in half-life was observed (GMR [90% CI]: 2.09 [1.32-3.30]). Considering the high plasma protein binding (> 99%) and a 1.9-fold to 2.3-fold increase in the unbound fraction in patients, the PK of unbound daridorexant was also assessed. Compared with healthy subjects, Child-Pugh B patients had a higher AUC0-inf (GMR [90% CI] 1.60 [0.93-2.73]), a lower apparent plasma clearance (GMR [90% CI] 0.63 [0.37-1.07]), and the same doubling in the half-life observed for total daridorexant, whereas maximum plasma concentration and apparent volume of distribution were not different. Unbound daridorexant PK in Child-Pugh A patients did not differ from healthy subjects. In addition, the metabolic ratios (parent to metabolite), i.e., a marker of CYP 3A4 activity, of the two most abundant daridorexant metabolites were higher in patients with liver cirrhosis compared with healthy subjects. All treatment-emergent adverse events were transient and of mild or moderate intensity and no other treatment-related effects were apparent. CONCLUSIONS: No safety issue of concern was detected following administration of 25 mg of daridorexant in the study population. Moderate liver cirrhosis causes impaired hepatic clearance of unbound daridorexant, which prolongs the half-life. A 25-mg dose of daridorexant should, therefore, not be exceeded in Child-Pugh B patients. A dose adjustment is not required in Child-Pugh A patients, while avoidance of daridorexant in patients with Child-Pugh C cirrhosis is recommended. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT03713242.
引用
- Berger B, Dingemanse J, Sabattini G, et al. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin Pharmacokinet. 2021. PMID: 34002356. doi:10.1007/s40262-021-01028-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。